Research programme: HIV inhibitors - Collaborations Pharmaceuticals/Institute of Human Virology/Research Center of Biotechnology
Latest Information Update: 28 Feb 2024
At a glance
- Originator Collaborations Pharmaceuticals; Institute of Human Virology; Research Centre of Biotechnology RAS
- Class Antivirals
- Mechanism of Action HIV reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in HIV-infections in Russia
- 28 Feb 2024 No recent reports of development identified for preclinical development in HIV-infections in USA
- 06 Jan 2020 HIV inhibitors is available for licensing as of 06 Jan 2020. http://www.collaborationspharma.com/